Close

BeiGene (BGNE) Announces China NMPA Approval of BRUKINSA for Treatment of Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. NVDA
4. PPG
5. HDFCB:IN
6. HDB
7. META
8. WIT
9. HDFCAMC:IN
10. CRM


Go back to BeiGene (BGNE) Announces China NMPA Approval of BRUKINSA for Treatment of Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

June 18, 2021 4:30 PM EDT

Third approval for BRUKINSA in China and second approval in WM worldwide

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received conditional approval from the China National Medical Products... More